As of CNBC Investing Club’s November 19, 2026, report, the S&P 500 was on pace for a sixth consecutive daily decline. The index was roughly 7% below its October 6 record close of 7,818.93. The report described a pullback in AI-related stocks after Anthropic opened trading at $111.50 a share, up 34% from its $83 IPO price, then fell below $100. That account does not establish that Anthropic’s decline caused the broader market move.
Johnson & Johnson, meanwhile, announced that Memorial Hermann-Texas Medical Center in Houston would become the first hospital to commercially install its Ottava robotic surgical system. The hospital participated in Ottava’s clinical trials. In July 2026, the FDA authorized the system for 10 upper-abdominal general surgery procedures. J&J is seeking to compete in a robotic surgery market long dominated by Intuitive Surgical, but the report framed Ottava as a potential longer-term contributor rather than a near-term driver of results.
J&J also submitted its antipsychotic drug Caplyta to the FDA for approval to treat manic episodes associated with bipolar I disorder. The submission followed two late-stage studies that, according to the report, found significantly reduced manic symptoms compared with placebo as early as day three, with improvements sustained through week three. The proposed use had not been approved at the time of reporting.
Caplyta already had FDA approvals for other adult uses, including schizophrenia and depressive episodes associated with bipolar I or II disorder. Its third-quarter revenue rose 66% from a year earlier to $398 million, and its 2026 sales had passed $1 billion, according to the report. J&J shares were down about 7% from the preceding Friday’s record close despite the product developments.
